Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
huge overreaction to the abbott lab EUA for $5 test
Of course there was a gap that had to be closed. He mentioned a support level of 10.50, which was blown through big time, because of the gap. Support level is about 7.50.
...His chart DID show that HUGE gap.....
He just didn't mention it.
Get ready for blast off back UP!!
jmo
GREAT TIME for a short squeeze....
or for shorts to cover, anyway
Share Statistics
Avg Vol (3 month) 3 5.32M
Avg Vol (10 day) 3 20.53M
Shares Outstanding 5 70.71M
Float 66.46M
% Held by Insiders 1 1.24%
% Held by Institutions 1 94.59%
Shares Short (Aug 14, 2020) 4 7.16M
Short Ratio (Aug 14, 2020) 4 1.51
Short % of Float (Aug 14, 2020) 4 10.17%
Short % of Shares Outstanding (Aug 14, 2020) 4 10.04%
Shares Short (prior month Jul 15, 2020) 4 3.21M
Your video chart analysis is for the birds.
Looks like time to buy more. :)
Can't believe the selling this morning. ??????????
with full approval and commercialization, for sure, will be the preferred test, already considered more accurate than the antigen test, and once it proves out earlier detection- growth here will be wildly exponential
ABBOTT mentioned schools, i can guarantee you, those kids will not like Q-tips being shoved up their nostrils, FLDM's saliva test is the realistic solution.
looking back- sounds like until full approval they wont have enough hard data to prove the earlier detection:
https://www.theguardian.com/world/2020/may/01/us-germ-warfare-lab-creates-test-for-pre-infectious-covid-19-carriers
Scientists working for the US military have designed a new Covid-19 test that could potentially identify carriers before they become infectious and spread the disease, the Guardian has learned.
In what could be a significant breakthrough, project coordinators hope the blood-based test will be able to detect the virus’s presence as early as 24 hours after infection – before people show symptoms and several days before a carrier is considered capable of spreading it to other people. That is also around four days before current tests can detect the virus.
The test has emerged from a project set up by the US military’s Defense Advanced Research Projects Agency (Darpa) aimed at rapid diagnosis of germ or chemical warfare poisoning. It was hurriedly repurposed when the pandemic broke out and the new test is expected to be put forward for emergency use approval (EUA) by the US Food and Drug Administration (FDA) within a week.
“The concept fills a diagnostic gap worldwide,” the head of Darpa’s biological technologies office, Dr Brad Ringeisen, told the Guardian, since it should also fill in testing gaps at later stages of the infection. If given FDA approval, he said, it had the potential to be “absolutely a gamechanger”.
While pre-infectious detection would improve the efficiency of test-and-trace programmes as governments worldwide relax lockdowns, Darpa cautioned that it must wait until after FDA approval is given and the test can be put into practise for evidence of exactly how early it can pick up the virus.
“The goal of research is to develop and validate an early host blood response diagnostic test for Covid,” Prof Stuart Sealfon, who leads the research team at Mount Sinai hospital in New York, said in an email.
He said the testing approach, which looks at the body’s response as it fights Covid-19, should produce earlier results than current nose-swab tests that hunt for the virus itself. “Because the immune response to infection develops immediately after infection, a Covid signature is expected to provide more sensitive Covid infection diagnosis earlier,” he told the Guardian.
The research behind the development of the tests will eventually be made public, with the collaborating teams from medical schools at Mount Sinai, Duke University and Princeton expected to publish online, allowing scientists around the world to trial similar methods.
If EUA is granted, the test should start being rolled out in the US in the second half of May. Approval is not guaranteed, but Darpa scientists are enthusiastic about the potential impact as governments loosen lockdowns amid worries about controlling potential second-wave outbreaks.
“We are all extremely excited. We want to roll this test out as quickly as we can, but at the same time share with others who might want to implement in their own countries,” said Dr Eric Van Gieson, who set up Darpa’s epigenetic characterization and observation (Echo) programme last year to diagnose biological warfare victims, and has redirected it to focus on Covid-19. Epigenetics looks at a set of controls on genes that can respond to the environment.
Hope that the test might pick up carriers before they become infectious is based on previous research into other viruses, though Sealfon said this remained “unknown” for Covid-19.
“We have evidence that diagnosis happens in the first 24 hours for influenza and an adenovirus,” Van Gieson said. “We are still in the midst of proving that with Covid-19. That said, we should know very soon after EUA.” He sees potential for the US to carry out up to a million tests a day, starting with 100,000 daily in May.
The test would up the possibility of isolating pre-infectious cases and closing down transmission chains. It could also dramatically reduce quarantine periods for people exposed to Covid-19 spreaders, allowing them to go back to work within days. “It could have exceptional demand,” said Chris Linthwaite, the chief executive of Fluidigm, a California life-sciences technology company that is part of the project, who believes frequent testing can help manage workforces as they return to offices, warehouses and factories.
The UK government announced plans two weeks ago to restart a contact-tracing programme that was abandoned early in the outbreak. Britain’s stated target was 100,000 tests a day by the end of April. France announced on Tuesday that it would test 700,000 people a week, including those without symptoms.
Other countries such as South Korea, Australia and New Zealand already have efficient tracing systems, but they would be boosted if carriers could be detected early.
Play Video 5:58
Coronavirus tests: how they work and what they show
Darpa experts also see potential to improve protocols for protecting health care workers and others in high-risk jobs, as well as those in relatively self-contained or isolated communities such as care homes and prisons or onboard ships.
The test uses the same polymerase chain reaction (PCR) machines used for checking nasal swabs from people suspected of having the virus. “It’s a simple tweak,” said Van Gieson. “The infrastructure is already there.”
wow- ok- i'm surprised they didn't highlight the earlier detection aspect in the news release-
also surprised to see it below $10
yes, this is the one, if ABT can add $18B just today with similar news, imagine what $18B market cap is for FLDM.
agree, this will go much higher.
is this test that was given EUA the one developed w DARPA?
the DARPA test, as reported in the guardian is a test that gives results before symptomatic - which is what is needed and a game changer- but assuming since that was not in PR at all , that that is another test we are still awaiting EUA for too?
$FLDM!
ABBOTT just added $18 B to its market cap on similar news, ours is better coz its Saliva, u do the Math.
* * $FLDM Video Chart 08-26-2020 * *
Link to Video - click here to watch the technical chart video
Not possible , imho 120 m traded today .... think about it
We stayed in sam range The Whole day ....
I bet at least 50 m shares were added to float today .. ?
maybe some institutions sold today, but its still tightly held by a lot of institutional investors.
If only 10% of the os was tradable then we would been in the 100s ... someone sold shares ... that’s all I’m saying
Impossible ....
So, are you saying dilution is likely or unlikely? Thanks again
$FLDM Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19
http://investors.fluidigm.com/news-releases/news-release-details/fluidigm-granted-fda-emergency-use-authorization-saliva-based
Fluidigm Files for FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR ... https://finance.yahoo.com/news/fluidigm-files-fda-emergency-authorization-000010742.html?soc_src=social-sh&soc_trk=tw via
$FLDM Huge News US Germ Warfare_Research_Leads_To_New_Early Covid-19_Test
Link:
https://www.theguardian.com/world/2020/may/01/us-germ-warfare-lab-creates-test-for-pre-infectious-covid-19-carriers
twitter https://twitter.com/fluidigm
FB updates
https://www.facebook.com/Fluidigm
corp link
https://www.fluidigm.com/?fbclid=IwAR1nxT-7hKCCSYfWJjRk21733trDqIRUb0nIzDAz4CzacAGxVencWej-WZM
FLDM Major Holders Breakdown
1.24% % of Shares Held by All Insider
94.59% % of Shares Held by Institutions
95.77% % of Float Held by Institutions
148 Number of Institutions Holding Shares
True MB. Do you see any dilution taking place here?
anytime, If KODAK can run to $60 with nothing, this may actually do it.
That would be sweet. Hope you are correct. Thanks
I agree with CITRONS's $35 target
this is the only FDA approved Saliva test for COVID, NBA was even pushing for this Saliva testing tech to test their players.
If so then where do you see this going short term?
There has to be some dilution going on
Why are we losing the gain so quickly?
yep let it go got the approval finally took awhile but it's there :)
Ok enough of this premarket hold back, LET HER BLOW!
Time to add more.
Finally. How exciting!!
Go FLDM. Great news!
I’ve been waiting on this!
$FLDM Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Advanta™ Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus, designed to be run on the Fluidigm® Biomark™ HD microfluidics platform.
Because it is saliva-based, the Advanta Dx SARS-CoV-2 RT-PCR Assay does not require collection via invasive nasopharyngeal swab. The clinical study associated with the EUA submission demonstrated 100 percent agreement between the saliva results from the Advanta Dx SARS-CoV-2 RT-PCR Assay and the results from paired nasopharyngeal samples tested with authorized assays.
“Accessible and accurate testing programs that include a non-invasive, saliva-based collection option will be essential throughout duration of the COVID-19 pandemic”, said Andrew Lukowiak Ph.D, CEO of San Diego-based Millennium Health, one of several high-complexity labs certified under the Clinical Laboratory Improvement Amendments (CLIA) in the United States that has been evaluating the Advanta Dx SARS-CoV-2 RT-PCR Assay in advance of authorization.
“In addition to the attractive sample input we chose the Fluidigm workflow because it combines extraordinary throughput per system with a robust supply chain from a trusted large-scale supplier. We believe this approach will enhance testing coverage in critical populations.”
The Advanta Dx SARS-CoV-2 RT-PCR test on the Biomark HD platform provides throughput advantages that reduce the impact of capacity-constrained supply chains. The company’s microfluidics technology enables processing of more samples per batch than more traditional, microwell plate-based PCR technology. The Biomark HD platform can generate as many as 6,000 test results per day on a single system.
“We have seen extraordinarily strong customer interest in our high-throughput saliva-based test, including many new purchases of Biomark HD systems to enable its adoption,” said Chris Linthwaite, President and CEO of Fluidigm. “We have a high degree of confidence that this new test will not only enhance testing capacity but will also significantly improve speed to results and scale. The ease of use for health care providers and patients alike will enable improved testing access to the global population. Fluidigm is excited to commercialize this easily administered saliva-based COVID-19 test during a critical phase of the pandemic.
“In the United States, Emergency Use Authorization for our test coincides with the total number of COVID-19 cases exceeding 5.7 million, underscoring the need for scalable and easy-to-administer testing.”
Fluidigm was recently selected by the National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering, for a proposed project under the agency’s Rapid Acceleration of Diagnostics (RADx) program. RADx fast-tracks development and commercialization of innovative technologies to significantly increase U.S. testing capacity for SARS-CoV-2.
The project, with a total proposed budget of up to $37 million, contemplates expanding production capacity and throughput capabilities for COVID-19 testing with Fluidigm microfluidics technology. The RADx project envisions both a major expansion of microfluidics manufacturing capacity and commercialization of a novel barcoding chemistry to further increase test throughput per system.
The Advanta Dx SARS-CoV-2 RT-PCR Assay was developed in collaboration with scientists at the McDonnell Genome Institute and the Department of Genetics at the Washington University School of Medicine in St. Louis.
Fluidigm’s ongoing collaboration with the Defense Advanced Research Projects Agency (DARPA) and its Epigenetic CHaracterization and Observation (ECHO) program includes financial support for development of innovative programs based on our microfluidics technology.
The RADx project has been funded in whole or in part with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under contract no. 75N92020C00009.
https://ih.advfn.com/stock-market/NASDAQ/fluidigm-FLDM/stock-news/83137057/fluidigm-granted-fda-emergency-use-authorization-f
Finally! Calls gonna blow up!
BOOM let's test it today on saliva test EUA granted!
4 am print at $22! $FLDM!
Oh my,
Going over $20 tomorrow
$FLDM - Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19
https://finance.yahoo.com/news/fluidigm-granted-fda-emergency-authorization-030000078.html
Followers
|
15
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
599
|
Created
|
05/01/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |